Adenoviruses are among the most attractive Viral Vectors for gene therapy because of their well-defined biology and characteristics. They have a high packaging capacity and can accommodate large transgene inserts of sizes up to ~8 kb. Adenovirus vectors also have high transduction efficiency and they can infect both dividing and non-dividing cells in a broad range of cell and tissue …
Annexin Pharmaceuticals AB and CDMO Biovian Oy released the First-In-Class ANXV drug candidate for clinical trials. Following a clinical study in healthy subjects, clinical trials with the drug will target retinal vein occlusion, a condition …
Affibody AB, a Swedish biotech company focused on developing next-generation biopharmaceuticals has selected Biovian Oy, the leading Nordic One-Stop-Shop CDMO for biopharmaceuticals as a CDMO partner for ABY-062 recombinant protein for clinical trial use. The …
A conversation with Pirjo Merilahti, PhD., Virology. At Biovian, Viral Vector process development is planned and executed by a team of experienced scientists, led by Dr Pirjo Merilahti. Her team typically starts the project with …
Take Advantage of One-on-One Partnering! Schedule a virtual meeting with Magnus Gustafsson, the Head of Global Business Development of Biovian and find out how we can help your gene therapy or biopharma project from the …
The therapeutic possibilities of cell and gene therapy are very appealing. The possibility to use a Viral Vector to carry the therapeutic gene into the target cells or to initiate cell transduction holds the potential …
Biovian, a Nordic Bio-CDMO is presented in the Biopharma Dealmakers’ June edition that focuses on next-generation therapeutics. The article describes Biovian’s concept of a true One-Stop-Shop that covers both the supply chain and the value chain.
